| Suspended | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy NCT05064111 | University of Arizona | — |
| Recruiting | Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response NCT06831032 | University Health Network, Toronto | N/A |
| Not Yet Recruiting | Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer NCT07468903 | Jonsson Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer NCT07364071 | University of California, San Diego | Phase 2 |
| Recruiting | Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With NCT06654336 | Ontario Clinical Oncology Group (OCOG) | Phase 2 |
| Recruiting | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance NCT07285057 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer NCT07251829 | Srinivas Raman | Phase 2 |
| Recruiting | Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Me NCT06957691 | Shehzad Basaria, M.D. | Phase 2 |
| Recruiting | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement NCT06200259 | Covenant Health Cancer Center | N/A |
| Not Yet Recruiting | Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Ris NCT07210502 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patie NCT07025369 | Mayo Clinic | Phase 2 |
| Recruiting | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers NCT06967961 | Institut Claudius Regaud | N/A |
| Recruiting | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatect NCT06798558 | Hackensack Meridian Health | Phase 2 |
| Recruiting | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN T NCT06813898 | Northwestern University | EARLY_Phase 1 |
| Recruiting | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients W NCT05726292 | University of Chicago | Phase 2 |
| Recruiting | A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer NCT06736054 | Hoag Memorial Hospital Presbyterian | Phase 1 |
| Recruiting | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostat NCT06022822 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Two-fraction HDR Monotherapy for Localized Prostate Cancer NCT05665738 | University of California, San Francisco | N/A |
| Recruiting | Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate NCT06499870 | Northwestern University | Phase 2 |
| Recruiting | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer NCT06330805 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prosta NCT06470750 | Mayo Clinic | — |
| Recruiting | Impact of Intraoperative ICG on Functional Outc in RARP NCT06446648 | University of California, Irvine | EARLY_Phase 1 |
| Recruiting | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer NCT06392295 | University of Miami | Phase 2 |
| Recruiting | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy NCT05919329 | OHSU Knight Cancer Institute | Phase 4 |
| Recruiting | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer NCT06257693 | Alessa Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study NCT05960578 | University of Washington | Phase 2 |
| Completed | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostat NCT06312670 | Pedro Barata, MD, MSc | Phase 2 |
| Recruiting | ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical NCT06141993 | Duke University | — |
| Not Yet Recruiting | Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Pa NCT06387238 | Peking University First Hospital | N/A |
| Recruiting | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer NCT06369610 | Mayo Clinic | Phase 2 |
| Completed | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer NCT06235099 | Curium US LLC | Phase 3 |
| Recruiting | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer NCT06235151 | Curium US LLC | Phase 3 |
| Recruiting | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Can NCT06518226 | UMC Utrecht | N/A |
| Recruiting | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patien NCT06067269 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | PSMA PET Response Guided SabR in High Risk Pca NCT06044857 | University of Texas Southwestern Medical Center | Phase 1 |
| Recruiting | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BR NCT05806515 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Can NCT05600400 | Sunnybrook Health Sciences Centre | N/A |
| Recruiting | Prostatic Size Reduction Following of Leuprorelin Acetate NCT06184464 | Consorci Sanitari de Terrassa | — |
| Recruiting | Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RA NCT06238713 | Shanghai Changzheng Hospital | N/A |
| Recruiting | Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound NCT05610852 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prost NCT05946213 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients NCT06105918 | Emory University | Phase 1 |
| Recruiting | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor NCT05616650 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction NCT05109208 | Mayo Clinic | N/A |
| Recruiting | Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes NCT05832086 | Stephen Freedland | Phase 2 |
| Recruiting | Personalized Optimization of Systematic Prostate Biopsy NCT05998278 | Fujian Medical University Union Hospital | N/A |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Unknown | SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer NCT05919524 | Almudena Zapatero | N/A |
| Recruiting | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Acti NCT05852041 | Northwestern University | EARLY_Phase 1 |
| Active Not Recruiting | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer NCT05779943 | Emory University | Phase 2 |
| Recruiting | MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy NCT05710380 | University of Chicago | N/A |
| Recruiting | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progr NCT06292897 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — |
| Recruiting | Dose De-escalation in Prostate Radiotherapy Using the MRL NCT05709496 | Royal Marsden NHS Foundation Trust | N/A |
| Completed | The Efficacy of Mapping for Cognitive Prostate Biopsy NCT05902637 | Marmara University | N/A |
| Recruiting | High-Risk prostatE Cancer radiatiOn Versus surgERy NCT05931419 | Comprehensive Cancer Centre The Netherlands | — |
| Terminated | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Canc NCT05679388 | University of Chicago | Phase 1 |
| Active Not Recruiting | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer NCT05751434 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. NCT05276492 | University of Chicago | Phase 1 |
| Active Not Recruiting | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression NCT05683964 | Beth Israel Deaconess Medical Center | EARLY_Phase 1 |
| Completed | Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for NCT06029088 | Ankara Etlik City Hospital | — |
| Withdrawn | Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate NCT05647447 | University of Kansas Medical Center | EARLY_Phase 1 |
| Terminated | Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate NCT05607342 | University of Kansas Medical Center | EARLY_Phase 1 |
| Completed | Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study NCT06299046 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — |
| Terminated | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer NCT05676463 | Thomas Jefferson University | Phase 2 |
| Terminated | Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatiti NCT04252625 | University of Utah | Phase 2 |
| Terminated | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma NCT04951492 | University of Washington | Phase 2 |
| Active Not Recruiting | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, T NCT05496959 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL NCT05599737 | Centre Leon Berard | N/A |
| Completed | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate C NCT04543903 | Alpha Tau Medical LTD. | N/A |
| Recruiting | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT04704505 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, NCT05053152 | NRG Oncology | Phase 2 |
| Unknown | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy NCT05224024 | Ankara University | N/A |
| Completed | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain NCT05803096 | Beth Israel Deaconess Medical Center | Phase 4 |
| Active Not Recruiting | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer NCT04943536 | Alessa Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for NCT05050084 | NRG Oncology | Phase 3 |
| Completed | Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With P NCT04870515 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer NCT05027477 | Profound Medical Inc. | N/A |
| Recruiting | Customized TULSA-PRO Ablation Registry NCT05001477 | Profound Medical Inc. | — |
| Completed | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion NCT04976257 | Ryan Kohlbrenner, MD | EARLY_Phase 1 |
| Completed | Fluorescent Imaging of Nerves With Illuminare-1 During Surgery NCT04983862 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic La NCT05735223 | Larkin Health System | N/A |
| Completed | 68Ga-PSMA-11 PET in Patients With Prostate Cancer NCT05197257 | University of Colorado, Denver | Phase 3 |
| Active Not Recruiting | Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer NCT04985565 | M.D. Anderson Cancer Center | N/A |
| Recruiting | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma NCT04945642 | Jonsson Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer NCT05055843 | M.D. Anderson Cancer Center | N/A |
| Completed | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy P NCT04978675 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer NCT05003752 | German Oncology Center, Cyprus | Phase 1 / Phase 2 |
| Terminated | Ga-68-PSMA-11 in Men With Prostate Cancer NCT05744115 | Timothy Hoffman | Phase 3 |
| Active Not Recruiting | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Rem NCT04530552 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer NCT04743934 | Andrew McDonald | Phase 2 |
| Recruiting | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Ca NCT04915508 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients NCT04946214 | University of Miami | N/A |
| Active Not Recruiting | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer NCT04777071 | University of Washington | Phase 2 |
| Active Not Recruiting | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Pro NCT04519879 | City of Hope Medical Center | Phase 2 |
| Unknown | ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features NCT04825691 | Assiut University | — |
| Terminated | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load NCT04336943 | University of Washington | Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Active Not Recruiting | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy NCT04053842 | Glenn Bauman | Phase 2 |
| Active Not Recruiting | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low NCT04513717 | NRG Oncology | Phase 3 |
| Recruiting | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE NCT05022914 | Azienda Ospedaliero-Universitaria Careggi | — |
| Completed | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prosta NCT03698370 | Andrei Iagaru | Phase 2 |
| Recruiting | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) NCT04486755 | University of Maryland, Baltimore | Phase 1 |
| Withdrawn | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer NCT04331717 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Tr NCT04624256 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | Trial of NanoPac Focal Therapy for Prostate Cancer NCT04221828 | NanOlogy, LLC | Phase 2 |
| Completed | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects NCT04288687 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC NCT04446117 | Exelixis | Phase 3 |
| Completed | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostat NCT04284761 | Alessa Therapeutics Inc. | Phase 1 |
| Recruiting | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET NCT04423211 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection NCT05589558 | I.M. Sechenov First Moscow State Medical University | N/A |
| Recruiting | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Ca NCT04175431 | University of Washington | Phase 2 |
| Completed | Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma NCT04391556 | Centre Leon Berard | Phase 2 |
| Completed | PROState Pathway Embedded Comparative Trial NCT04400656 | Imperial College London | — |
| Withdrawn | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in P NCT03982173 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) NCT04638049 | University Hospital, Ghent | N/A |
| Active Not Recruiting | Clinical Trial of Green Tea Catechins in Men on Active Surveillance NCT04300855 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer NCT04428203 | Zin W Myint | Phase 1 |
| Terminated | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Anti NCT04085991 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Recruiting | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer NCT04465500 | University of Virginia | Phase 2 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Active Not Recruiting | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate NCT04384770 | Jonsson Comprehensive Cancer Center | — |
| Active Not Recruiting | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors NCT04126070 | Xiao X. Wei, MD | Phase 2 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Recruiting | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery NCT04134260 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 NCT04045717 | Universitaire Ziekenhuizen KU Leuven | Phase 2 |
| Withdrawn | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer NCT04399824 | Jonsson Comprehensive Cancer Center | N/A |
| Unknown | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer NCT04192890 | I.M. Sechenov First Moscow State Medical University | N/A |
| Active Not Recruiting | A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer NCT04190446 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam NCT04286386 | M.D. Anderson Cancer Center | — |
| Completed | Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer NCT04049747 | Imperial College London | N/A |
| Active Not Recruiting | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before NCT03899987 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Pr NCT04020094 | University of Utah | Phase 2 |
| Completed | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation The NCT03830164 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Pros NCT03821246 | David Oh | Phase 2 |
| Terminated | Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With P NCT03718338 | University of Washington | — |
| Completed | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Thera NCT04037254 | NRG Oncology | Phase 1 / Phase 2 |
| Recruiting | Active Surveillance for Low Risk Prostate Cancer NCT04146077 | I.M. Sechenov First Moscow State Medical University | — |
| Active Not Recruiting | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer NCT03796767 | University of Utah | Phase 2 |
| Unknown | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer NCT04031378 | Fundacao Champalimaud | Phase 2 |
| Completed | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors NCT03860961 | NRG Oncology | N/A |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer NCT03963739 | Wake Forest University Health Sciences | — |
| Active Not Recruiting | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer NCT04030338 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer NCT04019327 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Defining Recurrent Disease With Axumin™ NCT03996993 | Cancer Center of Irvine | — |
| Completed | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT03805594 | University of California, San Francisco | Phase 1 |
| Active Not Recruiting | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes NCT03762759 | Emory University | Phase 2 |
| Recruiting | Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostat NCT03880422 | Roswell Park Cancer Institute | N/A |
| Terminated | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer NCT03829930 | George Washington University | Phase 1 |
| Withdrawn | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response NCT03581500 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine NCT06347809 | Mayo Clinic | — |
| Completed | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer NCT03739684 | Progenics Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Trea NCT03553212 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | N/A |
| Active Not Recruiting | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Me NCT03361735 | City of Hope Medical Center | Phase 2 |
| Completed | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer NCT03516812 | University of Washington | Phase 2 |
| Completed | Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer NCT03654638 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance NCT03933670 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | CyberKnife Dose Escalation Prostate Cancer Trial NCT03822494 | Crozer-Keystone Health System | N/A |
| Withdrawn | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC NCT03494803 | HKGepitherapeutics | — |
| Unknown | Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer NCT03255135 | Hospital de Transplante Doutor Euryclides de Jesus Zerbini | N/A |
| Active Not Recruiting | Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial) NCT03561961 | Tata Memorial Centre | N/A |
| Completed | Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatec NCT03570827 | Mayo Clinic | Phase 2 |
| Completed | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer. NCT03504995 | I.M. Sechenov First Moscow State Medical University | N/A |
| Completed | Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma NCT03496844 | University of Arizona | N/A |
| Completed | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer NCT04050215 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy NCT03412396 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence NCT03396874 | University of Michigan | Phase 2 |
| Unknown | Ischemic Heart Disease in Male With Prostate Adenocarcinoma NCT03474835 | Dnipropetrovsk State Medical Academy | N/A |
| Unknown | Early and Accurate Detection of Prostate Cancer in General Practice NCT03431753 | Aarhus University Hospital | N/A |
| Terminated | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance NCT02721979 | University of Washington | Phase 2 |
| Completed | Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI NCT03404648 | Mayo Clinic | Phase 3 |
| Completed | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Particip NCT03279250 | M.D. Anderson Cancer Center | Phase 2 |
| Enrolling By Invitation | Hemi-Gland Cryoablation for Prostate Cancer at UCLA NCT03503643 | Jonsson Comprehensive Cancer Center | — |
| Active Not Recruiting | A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer NCT03246347 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With P NCT03274687 | NRG Oncology | Phase 3 |
| Completed | CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cance NCT03780023 | University of California, Davis | — |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | PSMA PET Imaging of Recurrent Prostate Cancer NCT03204123 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Local NCT03177460 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment NCT02673151 | Andrei Iagaru | Phase 2 / Phase 3 |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Unknown | Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer NCT03451812 | Chang Gung Memorial Hospital | — |
| Completed | 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery NCT03368547 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Canc NCT03034070 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Completed | Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy NCT02940262 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Terminated | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients NCT02853097 | University of Southern California | — |
| Terminated | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk NCT02454517 | Fred Hutchinson Cancer Center | N/A |
| Unknown | Prostate Cancer - Localized Adenocarcinoma Proton Therapy NCT03285815 | National Cancer Center, Korea | N/A |
| Completed | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer NCT02624518 | Andrei Iagaru | Phase 2 / Phase 3 |
| Terminated | MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca NCT02564549 | Virginia Commonwealth University | N/A |
| Completed | Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors NCT02600156 | Mayo Clinic | N/A |
| Terminated | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant P NCT02491411 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 NCT02981797 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Active Not Recruiting | High-Dose Brachytherapy in Treating Patients With Prostate Cancer NCT02346253 | Stanford University | N/A |
| Completed | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors NCT02285101 | Bio-Cancer Treatment International Limited | Phase 1 |
| Completed | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate NCT02268175 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate NCT02254746 | Centre Hospitalier Universitaire Vaudois | N/A |
| Terminated | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Pa NCT02168062 | University of California, San Francisco | Phase 2 |
| Unknown | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer NCT02031328 | Sunnybrook Health Sciences Centre | Phase 1 / Phase 2 |
| Completed | CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer NCT01985828 | Wake Forest University Health Sciences | N/A |
| Completed | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer NCT01787331 | University of California, San Francisco | Phase 2 |
| Completed | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery NCT02603965 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Active Not Recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy NCT01953640 | Mayo Clinic | — |
| Completed | Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer NCT01731912 | University of Washington | N/A |
| Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant NCT02228265 | OHSU Knight Cancer Institute | — |
| Terminated | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer NCT01737151 | Virginia Commonwealth University | N/A |
| Active Not Recruiting | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurren NCT01786265 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate NCT01856855 | John Fiveash, MD | N/A |
| Withdrawn | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management NCT01838265 | University of Miami | — |
| Active Not Recruiting | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial NCT01411345 | University of Miami | N/A |
| Completed | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Res NCT01505868 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer NCT01898065 | Institut Cancerologie de l'Ouest | Phase 2 |
| Completed | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma NCT01530269 | Phoenix Molecular Imaging | Phase 2 |
| Completed | Tivantinib in Treating Patients With Metastatic Prostate Cancer NCT01519414 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robot NCT01661166 | Abramson Cancer Center at Penn Medicine | Phase 4 |
| Completed | MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer NCT01411319 | University of Miami | N/A |
| Unknown | An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer NCT01478412 | John Chang, MD | — |
| Completed | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer NCT01325311 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial NCT01411332 | University of Miami | N/A |
| Completed | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer NCT01347788 | Massachusetts General Hospital | Phase 1 |
| Completed | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly D NCT01120236 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Aden NCT01219790 | Institut Cancerologie de l'Ouest | Phase 1 |
| Terminated | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistan NCT01145508 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Lo NCT01148069 | Rennes University Hospital | Phase 2 |
| Terminated | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After Firs NCT01253642 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients Wi NCT01163084 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer NCT01026623 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer NCT01352429 | Abramson Cancer Center at Penn Medicine | — |
| Terminated | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate NCT00937768 | Mayo Clinic | Phase 2 |
| Completed | Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation NCT00887432 | Roswell Park Cancer Institute | N/A |
| Completed | Patients Overexposed for a Prostate Adenocarcinoma NCT00773656 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Locali NCT00589472 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma NCT01709253 | National Cancer Center, Korea | N/A |
| Terminated | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate NCT00536991 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | 131-I-TM-601 Study in Adults With Solid Tumors NCT00379132 | TransMolecular | Phase 1 |
| Completed | Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma NCT02339948 | GenesisCare USA | N/A |
| Completed | Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer NCT02175212 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Phase 3 |
| Completed | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer NCT00170157 | Mayo Clinic | Phase 2 |
| Completed | Trilostane for Androgen-Independent Prostate Cancer NCT00181597 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing Afte NCT00183924 | University of Southern California | Phase 2 |
| No Longer Available | Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer NCT05415228 | Morand Piert, MD | — |
| No Longer Available | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer NCT03501940 | Andrei Iagaru | — |
| Approved For Marketing | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer NCT04377152 | University of California, San Francisco | — |